Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-CHCHD-001 in ALS Due to CHCHD10 Mutation
NCT07423494Phase 2Not yet recruiting
- Sponsor
- n-Lorem Foundation
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of nL-CHCHD-001 in amyotrophic lateral sclerosis (ALS), sponsored by n-Lorem Foundation. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
nL-CHCHD-001
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07423494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423494.